Program
SSGJ-706
A development code. Also written as “SSGJ-706+Bevacizumab+XELOX”, “SSGJ-706+AG” and “SSGJ-706+TP”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms, led by 3SBio.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| 3SBio | 43 open or running | phase 2since Sep 1, 2025 | Jul 29, 2024 | Dec 2026phase 2 · NCT07233850 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 29, 2024First study: phase 1 study in Advanced Solid Tumors PatientsFirst studyNCT06533605 · 60 enrolled
- Sep 1, 2025Phase 2 study in First-line Advanced NSCLC PatientsNCT07171606 · 240 planned · China
- Nov 14, 2025Phase 2 study in Colorectal NeoplasmsNCT07233850 · 300 planned · China
- Sep 20, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07874984 · 220 planned
Ahead
- Dec 2026Primary completion: phase 2 study in Colorectal NeoplasmsNCT07233850
- Nov 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07874984
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07874984Carcinoma, Non-Small-Cell Lung | 2 | Not yet recruiting | Nov 2027 | 220 |
| NCT07233850Colorectal Neoplasms · China | 2 | Not yet recruiting | Dec 2026 | 300 |
| NCT07171606First-line Advanced NSCLC Patients · China | 2 | Recruiting | Aug 31, 2026 | 240 |
| NCT06533605Advanced Solid Tumors Patients | 1 | UNKNOWN | Jul 30, 2025 | 60 |
How it is read
Names in the registry
- “SSGJ-706”, 3 entries
- “SSGJ-706+Bevacizumab+XELOX”, 1 entry
- “SSGJ-706+AG”, 1 entry
- “SSGJ-706+TP”, 1 entry
Codes read as this program: SSGJ706.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.